Regulation of the novel mTOR suppressor DDIT4 in the failing heart

新型 mTOR 抑制剂 DDIT4 在衰竭心脏中的调节

• 批准号: 8244427
• 负责人: YINGJIE CHEN
• 金额: $ 18.88万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8244427
• 关键词: 5' -AMP-activated protein kinase; 70-kDa Ribosomal Protein S6 Kinases; Attenuated; Cardiac Myocytes; Cartoons; Cell Line; Chronic; Chronic stress; Complex; DNA Damage; Development; Disease; Fibrosis; Figs - dietary; Foundations; Functional disorder; Genes; Heart; Heart failure; Hypertrophy; In Vitro; Intervention; Knowledge; Lead; Left; Left Ventricular Hypertrophy; Link; Mediating; Metformin; Molecular; Mouse Strains; Mus; Myocardial; Pathway interactions; Phenylephrine; Physiological; Play; Proteins; Publishing; Regulation; Relative (related person); Role; Signal Pathway; Signal Transduction; Stress; TSC1 gene; TSC2 gene; Testing; Transcript; Tumor Cell Line; Tumor-Derived; Ventricular; Ventricular Dysfunction; Work; base; cell growth; clinically relevant; constriction; hemodynamics; human FRAP1 protein; innovation; insight; mTOR protein; novel; overexpression; public health relevance; response; tumor; ventricular hypertrophy

DESCRIPTION (provided by applicant): AMP-activated protein kinase (AMPK) negatively regulates mammalian target of rapamycin (mTOR), the master regulator of translational machinery and cell growth. Recently, we demonstrated that the progressive left ventricular (LV) hypertrophy and heart failure (HF) caused by transverse aortic constriction (TAC) is exacerbated in mice with AMPK12 gene deficiency (AMPK12-/-), and this was associated with increased p- p70S6KThr389, a downstream target of mTOR complex 1 (mTORC1). We also found that activation of AMPK with AICAR or metformin, or overexpression of constitutively active AMPK12, all significantly attenuated cardiac myocyte hypertrophy and p-p70S6KThr389 in vitro. However, the mechanism by which loss of AMPK12 causes increased activation of the mTORC1/p-p70S6k Thr389 signaling pathway after TAC is not clear. DNA-damage-inducible transcript 4 (DDIT4) is a novel stress-responsive gene that negatively regulates the mTORC1 pathway in several tumor-derived cell lines. Although no published studies examining DDIT4 in the heart are available, using global microarray profiling we found that AMPK12-/- mice have decreased expression of myocardial DDIT4. These findings suggest that DDIT4 could provide the essential link by which AMPK12-/- causes activation of the mTORC1 and thereby exacerbates LV hypertrophy during stress conditions. Consequently, studies are proposed to determine whether the novel mTORC1 suppressor DDIT4 is instrumental in attenuating TAC-induced LV hypertrophy and HF in mice after TAC, and the molecular mechanisms by which AMPK12 facilitates adaptation of the heart to hemodynamic overload. Our central hypothesis is that DDIT4 attenuates chronic TAC-induced cardiac myocyte hypertrophy by attenuating the mTORC1 signaling pathway. We also hypothesize that AMPK regulates mTORC1 signaling at least partially through DDIT4. We plan to test our central hypothesis by pursuing the following two Specific Aims: i) Identify the overall impact of DDIT4 on myocardial mTORC1 signaling, LV hypertrophy and HF. Our working hypothesis is that DDIT4 gene deficiency (DDIT4-/-) will amplify activation of the mTOR signaling pathway and LV hypertrophy that occurs when hearts are exposed to systolic overload; ii) Determine the molecular mechanism by which AMPK attenuates mTORC1/p70s6k activation and cardiac myocyte hypertrophy. Our working hypothesis is that DDIT4 plays an essential role for AMPK to attenuate pathological LV hypertrophy. The project is innovative as no previous studies have examined the influence of DDIT4 on LV hypertrophy and HF. Using DDIT4-/- mice combined with TAC will allow us to decipher the role of DDIT4 in attenuating cardiac myocyte hypertrophy under clinically relevant conditions. This project is significant as the knowledge obtained will lead to a better understanding of the molecular mechanisms mediating ventricular hypertrophy and HF, which may provide the basis for developing specific interventions to treat these diseases. PUBLIC HEALTH RELEVANCE: DNA-damage-inducible transcript 4 (DDIT4) is a novel stress-responsive gene that negatively regulate the mTOR pathway in tumor cell lines. However, the effect of DDIT4 on ventricular hypertrophy and dysfunction has not been studied. Using global microarray profiling we recently found that AMPK12 KO mice have decreased expression of myocardial DDIT4, a change may explain the enhanced activation of myocardial mTOR signaling and ventricular hypertrophy in AMPK12 mice in response to chronic stress overload. Studies are proposed to determine whether the novel mTOR suppressor DDIT4 is instrumental in attenuating the development of ventricular hypertrophy and heart failure.

描述(申请人提供)：AMPK负性调节哺乳动物的雷帕霉素靶标(MTOR)，mTOR是翻译机制和细胞生长的主要调节因子。最近，我们证实了AMPK12基因缺陷(AMPK12-/-)小鼠由横断性主动脉缩窄(TAC)引起的进行性左室肥厚和心力衰竭(HF)加重，这与mTOR复合体1(MTORC1)下游靶点p-p70S6KThr389的增加有关。我们还发现，用AICAR或二甲双胍激活AMPK，或过表达固有活性的AMPK12，都能显著抑制体外培养的心肌细胞肥大和p-p70S6KThr389。然而，AMPK12缺失导致TAC后mTORC1/p-p70S6K Thr389信号通路激活增加的机制尚不清楚。DNA损伤诱导转录本4(DDIT4)是一种新的应激反应基因，在多种肿瘤细胞系中负调控mTORC1通路。虽然目前还没有研究心脏中DDIT4的公开研究，但是使用全球微阵列技术，我们发现AMPK12-/-小鼠心肌中DDIT4的表达减少。这些发现表明，DDIT4可能提供AMPK12-/-导致mTORC1激活的关键环节，从而在应激条件下加剧左室肥厚。因此，有人建议进行研究，以确定新型mTORC1抑制剂DDIT4是否有助于减轻TAC诱导的小鼠左室肥厚和TAC后的心衰，以及AMPK12促进心脏对血流动力学超负荷的适应的分子机制。我们的中心假设是，DDIT4通过减弱mTORC1信号通路来减轻TAC诱导的慢性心肌细胞肥大。我们还假设AMPK至少部分地通过DDIT4来调节mTORC1信号。我们计划通过追求以下两个具体目标来验证我们的中心假设：i)确定DDIT4对心肌mTORC1信号、左室肥厚和心衰的整体影响。我们的工作假设是，DDIT4基因缺陷(DDIT4-/-)将放大mTOR信号通路的激活和心脏收缩超负荷时发生的左室肥厚；ii)决定AMPK抑制mTORC1/p70S6K激活和心肌细胞肥大的分子机制。我们的工作假设是，DDIT4在AMPK减轻病理性左心室肥厚中起重要作用。该项目是创新的，因为以前没有研究过DDIT4对左室肥厚和心衰的影响。使用DDIT4-/-小鼠和TAC联合使用将使我们能够破译在临床相关条件下DDIT4在减轻心肌细胞肥大中的作用。这一项目具有重要意义，因为所获得的知识将有助于更好地理解介导心室肥厚和心力衰竭的分子机制，这可能为开发治疗这些疾病的特定干预措施提供基础。 公共卫生相关性：DNA损伤诱导转录本4(DDIT4)是一种新的应激反应基因，在肿瘤细胞系中负向调节mTOR途径。然而，DDIT4对心肌肥厚和功能障碍的影响还没有研究。利用全球芯片图谱，我们最近发现AMPK12 KO小鼠心肌DDIT4的表达减少，这一变化可能解释了AMPK12小鼠在慢性应激超负荷反应中心肌mTOR信号的激活增强和心室肥厚。有人建议进行研究，以确定新的mTOR抑制剂DDIT4是否有助于减轻心室肥厚和心力衰竭的发展。